Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Unfortunately, some tumor cells remain resistant to TRAIL. Therefore, agents that sensitize malignant cells to TRAIL-mediated cell death might be of particular importance for the development of novel antitumor therapeutic regimens. Recent studies establish a critical role of selenium in prostate cancer prevention in vitro and in vivo. Here, we demonstrate that concomitant administration of TRAIL and methylseleninic acid (MSA) produces synergistic effects on the induction of apoptosis in androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells. MSA rapidly and specifically downregulates expression of the cellular FLICE inhibitory protein, a negative regulator of death receptor signaling. In addition, we demonstrate that the synergistic effects of MSA and TRAIL result from the activation of the mitochondrial pathway-mediated amplification loop. Addition of MSA effectively blocked TRAIL-mediated BAD phosphorylation at Ser112 and Ser136 in DU-145 cells and was accompanied by induction of the mitochondrial permeability transition and release of apoptogenic cytochrome c and Smac/DIABLO proteins from the mitochondria and into the cytosol. These results suggest that selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prostate cancer cells.
Introduction
Apoptosis plays a critical role in embryonal development, immune regulation and tumor regression. Two major apoptotic signaling pathways have been identified: the death receptor-mediated (extrinsic) pathway and the mitochondrial (intrinsic) pathway (Ashkenazi and Dixit, 1998; Kroemer and Reed, 2000; Gupta, 2003; Debatin and Krammer, 2004; Henry-Mowatt et al., 2004) . The relative contribution of death receptor versus mitochondrial pathways in apoptosis reflects the existence of two different cell types. In type I cells, ligation of death receptor with subsequent activation of initiator and effector caspases is sufficient to induce nuclear apoptosis. In contrast, in type II cells, apoptosis is dependent on the amplification of death receptor signals via the mitochondrial pathway (Ozoren and El-Deiry, 2002; Wang and El-Deiry, 2003) . Death receptors are members of the TNF receptor gene family, which consists of a cysteine-rich extracellular domain and an intracellular death domain (DD) (Boldin et al., 1995; Baker and Reddy, 1998; Thorburn, 2004) . Activation of death receptors leads to the formation of a deathinducing signaling complex (DISC), composed of the receptor itself, the adapter protein FADD (Fas-associated death domain) and procaspase-8. Aggregation of procaspase-8 results in proteolytic activation and the subsequent activation of downstream apoptotic events (Chinnaiyan et al., 1995; Kischkel et al., 1995 Kischkel et al., , 2001 Debatin and Krammer, 2004) . The cellular FLICE inhibitory protein (cFLIP) regulates recruitment and processing of initiator caspases within DISC by competing with caspase-8 for binding to the DISC (Muzio et al., 1996; Scaffidi et al., 1999) . cFLIP is present in two main isoforms: cFLIP-long (FLIP L ) and cFLIP-short (FLIP S ). Both isoforms contain two death effector domain (DED) motifs that are similar to the DED on caspase-8 (Irmler et al., 1997; Thorburn, 2004) . Recent studies reveal that stable overexpression of either isoform of cFLIP results in resistance to death receptor-mediated apoptosis (Kataoka et al., 1998; Scaffidi et al., 1999) , while downregulation of cFLIP by siRNA sensitizes tumor cells of various origin to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis (Chawla-Sarkar et al., 2004; Mathas et al., 2004) .
Currently, TRAIL is being investigated as a new cancer therapeutic agent. Recent studies demonstrate that TRAIL induces apoptosis in various human tumors both in vitro and in vivo (Walczak et al., 1999; Walczak and Krammer, 2000; Debatin and Krammer, 2004) . Some cancers, however, display resistance to TRAIL, suggesting that treatment with TRAIL alone may be insufficient for cancer therapy. Naturally occurring dietary compounds have gained considerable attention as cancer chemopreventive agents. Recent studies demonstrated that several dietary compounds including curcumin (Deeb et al., 2004) and resveratrol (Fulda and Debatin, 2004) sensitize prostate cancer cells to TRAILmediated apoptosis.
Recently, substantial data have accumulated implicating mitochondria in apoptotic signaling pathways. Alterations in mitochondrial membrane structure and function activate both caspase-dependent and -independent cell death pathways. This is primarily due to the fact that after permeabilization of the mitochondrial outer membrane, a number of soluble proteins localized to the intermembrane space or matrix of the mitochondria translocate, and serve as caspase activators in the cytosol or stimulate endonuclease activity in the nucleus. The proteins involved in the activation of caspase family members include cytochrome c and Smac/DIABLO. Cytochrome c triggers activation of the caspase cascade by promoting apoptosome formation while Smac/ DIABLO antagonizes inhibitor of apoptosis proteins (IAPs), a family of cellular caspase inhibitors (HenryMowatt et al., 2004; Saelens et al., 2004) . The integrity of the mitochondrial membrane is controlled by the proand antiapoptotic members of Bcl-2 family. The antiapoptotic members include Bcl-2 and Bcl-X L proteins, whose overexpression renders cells resistant to a wide variety of apoptotic stimuli. Proapoptotic members of the Bcl-2 family can be divided into two sets according to the presence of domains homologous to Bcl-2 (BH domains). Bax and Bak proteins contain three BH domains and are localized in the cytosol and mitochondrial membrane. Other proapoptotic proteins containing a single BH domain serve either to inactivate antiapoptotic proteins or activate Bax or Bak (Gupta, 2003; Henry-Mowatt et al., 2004; Saelens et al., 2004) . Bad is a BH3-only protein that links survival signals to the mitochondrial cell death machinery (Zha et al., 1996; Korsmeyer et al., 1999; Datta et al., 2002) . Recent findings suggest that phosphorylation of Bad inactivates its proapoptotic activity (Zha et al., 1996; Datta et al., 2000 Datta et al., , 2002 Dramsi et al., 2002) . Upon dephosphorylation, the active form of Bad translocates to the mitochondria and heterodimerizes with Bcl-2 and Bcl-X L proteins, neutralizing their protective effect and promoting cell death (Zha et al., 1996; Hsu et al., 1997; Taghiyev et al., 2003) .
Selenium is a nonmetallic trace element essential to human health. Accumulating evidence suggests that selenium-based compounds might serve as potent prostate cancer preventative agents (Ip and Ganther, 1990; Ip et al., 2000; Dong et al., 2003; Klein et al., 2003; Zu and Ip, 2003) . This enthusiasm is reflected in the initiation of the large National Cancer Institute sponsored trial -SELECT (Selenium and Vitamin E Chemoprevention Trial). Selenomethionine (Se-Met) is the selenium compound used in SELECT (Klein et al., 2003) . However, it is not suitable for mechanistic studies in cell culture, whereas it needs to be metabolized, primarily in the liver, to a monomethylated intermediate for the expression of its anticancer activity (Ip and Ganther, 1990; Ip et al., 1991) . Epithelial tissues generally have a low capacity to generate a monomethylated selenium metabolite from Se-Met. To obviate this problem, methylseleninic acid (MSA) (CH 3 SeO 2 H) was developed specifically for in vitro studies (Ip et al., 2000) .
In the present study, we demonstrate that administration of MSA significantly enhances TRAIL-mediated apoptosis in prostate cancer cells. The proposed mechanism of sensitization includes activation of both the extrinsic and the intrinsic signaling pathways.
Results
MSA sensitizes androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells to TRAIL-mediated apoptosis
The cytotoxic effect of TRAIL in combination with MSA was evaluated in LNCaP and DU-145 cells using a DNA fragmentation assay. Treatment of prostate cancer cells with TRAIL alone for 24 h induced negligible levels of apoptosis. Treatment with MSA alone also failed to induce significant level of cell death in LNCaP cells, although, it induced notable apoptosis in DU-145. However, concomitant treatment with TRAIL and MSA resulted in profound DNA fragmentation in both LNCaP and DU-145 cells (74.3 and 61.5% correspondingly) (Figure 1 ). Statistical analysis confirmed a synergistic interaction of TRAIL and MSA in inducing apoptosis in prostate cancer cells (Po0.05).
Kinetics of cell death in DU-145 cells induced by TRAIL and MSA Next, we characterized the kinetics of cell death in DU-145 cells induced by TRAIL and/or MSA. When DU-145 cells were treated with either TRAIL or MSA alone, the background level of cytotoxicity (4-7%) remained invariably low throughout the 6 h time course (Figure 2a ). When DU-145 cells were treated with TRAIL and MSA simultaneously, a noticeable synergistic effect on the induction of apoptosis was detected as early as 4 h after treatment was initiated (35.1%) (Figure 2a ). To assess the potential involvement of caspase family members in this process, we tested whether the pan-caspase inhibitor Z-VAD.fmk could prevent DNA fragmentation in prostate cancer cells simultaneously treated with TRAIL and MSA. Figure 2b demonstrates that the pan-caspase inhibitor Z-VAD.fmk efficiently blocked apoptosis in DU-145 cells treated with TRAIL and MSA. Therefore, we demonstrate that apoptosis in prostate cancer cells treated with the combination of TRAIL and MSA is mediated via a caspase-dependent process.
MSA but not other selenium-containing compounds sensitizes DU-145 cells to TRAIL-mediated apoptosis
To establish whether other selenium-containing reagents also sensitize prostate cancer cells to TRAIL-mediated cell death, DU-145 cells were exposed to 5 mM of selenium in the form of MSA, sodium selenite, Se-Met or Se-(Methyl)selenocysteine for 6 h in the presence or absence of TRAIL. As demonstrated in Figure 3 , only the addition of MSA sensitized DU-145 cells to TRAILmediated apoptosis (42.1%), while sodium selenite (6.8%), Se-Met (4.9%) or Se-(Methyl)selenocysteine (7.8%) had no significant effect on the cell death in prostate cancer cells.
Expression of TRAIL receptor family members in MSA-treated DU-145 cells
TRAIL can bind to four cell surface receptors. Two of them carry a DD, and so they have been named death receptors 4 (DR4) and 5 (DR5) (Chaudhary et al., 1997; Pan et al., 1997b; Wu et al., 1999) . The two other TRAIL receptors lack a DD or have a partial DD and are named decoys, DcR1 and DcR2 (Degli-Esposti et al., 1997; Pan et al., 1997a; Ozoren and El-Deiry, 2003) . Recent evidence demonstrates that sodium selenite specifically upregulates expression of the DR5 receptor in DU-145 cells, and that this process is coupled with activation of caspase-8 . Therefore, we investigated the expression of the members of the TRAIL receptor family in DU-145 cells in response to MSA treatment. Figure 4 demonstrates that DU-145 cells constitutively express high levels of DR4 and DR5 receptors with significantly lower levels of expression of the decoy receptors, DcR1 and DcR2. MSA rapidly downregulated expression of DR4 and DcR2 in DU-145 cells, while it had almost no effect on the expression of two other members of TRAIL receptor family (DR5 and DcR1). Collectively, the above results suggest that the ability of MSA to enhance TRAILmediated apoptosis is not associated with upregulation of the agonist death receptors (DR4 and DR5) in prostate cancer cells.
MSA reduces expression of FLIP s protein in prostate cancer cells
To further explore the mechanism of MSA-mediated sensitization to TRAIL in prostate cancer cells, we examined the expression and status of activation of proteins involved in signaling through the cell death receptor pathway. As shown in Figure 5a , the addition of MSA facilitated proteolytic activation of caspases-8 and -3 and cleavage of intracellular caspase-3 substrate poly(ADP-ribose) polymerase (PARP) in DU-145 cells treated with TRAIL. We found that MSA rapidly and specifically downregulated the expression of FLIP s protein (Figure 5b ). The reduction of FLIP s protein levels in cells treated with MSA only was observed in the absence of detectable caspases-8 and -3 activity as documented by a lack of proteolytic processing of caspases-8 and -3 and PARP cleavage (Figure 5a ). Therefore, reduction of FLIP s expression was not simply a by-product of activation of a cell death signaling cascade. Moreover, addition of the pan-caspase inhibitor Z-VAD.fmk failed to prevent downregulation of FLIP s protein in DU-145 cells treated with either MSA alone or the MSA/TRAIL combination (data not shown). Combined treatment also enhanced the cleavage-mediated inactivation of the antiapoptotic molecule RIP (Figure 5b ). Importantly, although treatment of DU-145 cells with TRAIL alone was capable of inducing noticeable level of caspases-8 and -3 activation (Figure 5a ), activation of caspase-9 and DNA fragmentation (o7%) was minimal in DU-145 cells treated with TRAIL only (Figures 1, 2 and 5a ). These data demonstrate the critical role of mitochondria in the full development of TRAILmediated apoptosis in prostate cancer cells.
MSA augments TRAIL-mediated apoptosis via activation of the mitochondrial arm of the apoptotic pathway
To determine whether synergy between TRAIL and MSA in apoptosis induction in prostate cancer cells was Figure 6a , TRAIL and MSA failed to induce significant level of MPT when used separately. In contrast, simultaneous addition of both reagents rapidly triggered MPT in DU-145 cells, which preceded apoptotic DNA fragmentation (Figure 2 and 6a ). This process was accompanied by release of apoptogenic cytochrome c and Smac/DIABLO proteins from the mitochondria into the cytosol (Figure 6b ). We also explored if TRAIL and MSA could affect the stability of some antiapoptotic proteins. Our data show that expressions of BCL-2, BCL-X L , c-IAP1, XIAP and survivin were not affected by treatment with TRAIL and MSA (Figure 7a ). The proapoptotic Bcl-2 family member BAD was the first cell death component to be identified as a regulatory target of survival signaling. Many growth factors, including IL-3, are key survival factors that suppress apoptosis via phosphorylation of BAD (Zha et al., 1996) . To explore whether the observed synergy between TRAIL and MSA in inducing apoptosis in prostate cancer cells was associated with modulation of Bad phosphorylation, we analysed phosphorylation of BAD at Ser112 and Ser136 in DU-145 cells exposed to TRAIL and MSA. Treatment of DU-145 with TRAIL resulted in phosphorylation of BAD at both sites, Ser112 and Ser136 (Figure 7b ). This observation indicates that resistance to TRAILmediated apoptosis in prostate cancer cells may be explained at least in part by the fact that TRAIL diminishes the cell suicide program by inactivating BAD protein via its phosphorylation. Addition of MSA effectively blocked TRAIL-mediated BAD phosphorylation at Ser112 and Ser136 in DU-145 cells (Figure 7b ). Phosphorylation of BAD precludes the BAD/BCL-X L complex formation, allowing protection of cells from apoptosis (Zha et al., 1996; Scheid et al., 1999; Chiang et al., 2001) . Therefore, we investigated association of BAD with BCL-X L in DU-145 cells treated with TRAIL and MSA. In DU-145 cells cultured in medium, BAD could be detected by Western blotting from the immunoprecipitate of BCL-X L, indicating the presence of BAD/BCL-X L heterodimers in untreated cells (Figure 7c ). Stimulation with TRAIL resulted in a complete loss of BAD/BCL-X L association, while addition of MSA prevented BAD/BCL-X L dissociation consistent with BAD phosphorylation status (Figure 7b and c). These results suggest one possible mechanism for the synergistic effect of TRAIL and MSA on the induction of apoptosis in prostate cancer cells and might have important consequences for the prevention and treatment of prostate cancer.
Discussion
The antitumor effect of selenium is executed at least in part through stimulation of apoptotic programs in susceptible cells. Recent studies have demonstrated that different selenium-containing compounds activate distinct cell death pathways in cancer cells. MSA-induced nucleosomal DNA fragmentation is accompanied by activation of various caspases, PARP cleavage and mitochondrial release of cytochrome c, whereas apoptotic DNA fragmentation induced by sodium selenite was observed in the absence of detectable caspase activity (Jiang et al., 2001; Kim et al., 2001) . Caspases family members are also essential executors of apoptosis induced by Se-(Methyl)selenocysteine (Kim et al., 2001) . In this study, we investigated the mechanism by which MSA augments TRAIL-induced cytotoxicity in prostate cancer cells and demonstrated that MSA modulates expression and activation of proteins involved in cell death signaling through both extrinsic and intrinsic pathways. Interestingly, among selenium-containing reagents, for example, MSA, sodium selenite, Se-Met and Se-(Methyl)selenocysteine, only MSA sensitized prostate cancer cells to TRAIL-mediated apoptosis (Figure 3 ). Previous studies in prostate and nonprostate cell lines have demonstrated that MSA exerted more powerful inhibitory effect on cell proliferation and viability than Se-Met and Se-(Methyl)selenocysteine (Ip et al., 2000; Dong et al., 2002; Venkateswaran et al., 2002; Zu and Ip, 2003) . One potential explanation is that MSA delivers monomethylated selenium species directly to cells (Ip et al., 2000) . Previous research confirmed that any precursor that directly generates a steady stream of methylselenol is more active than selenite or Se-Met (Ip and Ganther, 1990; Ip et al., 1991 Ip et al., , 2000 . Recent findings demonstrating the effect of TRAIL on the induction of apoptosis in various prostate cancer cell lines including DU-145 cells are not consistent. Some studies have demonstrated substantial sensitivity of DU-145 cells to TRAIL-mediated cell death Nesterov et al., 2001; Thakkar et al., 2001 ). In contrast, other studies demonstrated significantly lower levels of apoptosis for DU-145 cells treated with TRAIL alone (Zisman et al., 2001; Voelkel-Johnson et al., 2002) . In our experiments, treatment of DU-145 cells with TRAIL alone induced negligible levels of Figure 5 Western blot analysis of caspase processing and apoptosis-regulatory molecule expression. DU-145 cells were treated with TRAIL (1 mg/ml), MSA (5 mM) or the TRAIL/MSA combination for the indicated periods of time. Cell lysates were subjected to SDS-PAGE, blotted and probed with (a) antibodies to full-length and cleaved caspase-3, -8 and -9 and PARP protein; and (b) antibodies to FADD, RIP and FLIP s proteins. Expression of actin was used to control equal protein loading apoptosis (Figures 1 and 2) . We believe that inconsistent data on the sensitivity of prostate cancer cells to TRAIL-mediated apoptosis might be due to: (i) clonal diversity of cell lines used by different researchers; (ii) the purity of TRAIL preparations, e.g. presence of endotoxin; (iii) the solution behavior of particular TRAIL preparations, e.g. presence of crosslinking enhancer; the existence of trimeric structure, etc.; (iv) the nature of the assay used to assess cell death (MTT, TUNEL, cell cycle analysis of sub-G 1 population, etc.).
The mechanisms underlying the resistance to TRAIL are not completely understood. Although, TRAIL alone was capable of inducing activation of caspase-8 and -3 and PARP cleavage (Figure 5a ), activation of downstream components of the apoptotic cascade such as induction of MPT, cytochrome c and Smac/DIABLO translocation, activation of caspase-9 and DNA (Figure 6a and b). Our data are in agreement with recent studies demonstrating that phosphorylation of BAD inactivates its proapoptotic activity by preventing BAD/BCL-X L complex formation (Zha et al., 1996; Datta et al., 2000 Datta et al., , 2002 Dramsi et al., 2002) . It is interesting that the presence of BAD/BCL-X L heterodimers in DU-145 cells cultured in medium was insufficient to promote apoptosis. This may be explained by recent findings that the function of BAD may not merely be to passively inactivate BCL-X L (Chattopadhyay et al., 2001) . The possibility exists that additional factors are required to promote apoptosis in addition to BAD/BCL-X L complex formation. Taken together, these data reveal a potential mechanism for the synergistic effect of TRAIL and MSA on the induction of apoptosis in prostate cancer cells.
Resistance of tumor cells to anticancer therapies may result from failure to activate apoptotic pathways in response to drug treatment. The heterogeneity of cancer cells with respect to their sensitivity to various stress agents emphasizes the need for the activation of additional death pathways in the therapeutic control of cancer cell death. TRAIL cytotoxic activity was found to be relatively selective to the human tumor cell lines without much effect on the normal cells. TRAIL implements an antitumor activity without causing toxicity, as apparent by studies with several xenograft models (Srivastava, 2001) . Our results indicate that selenium-based compounds can sensitize both androgen-dependent and -independent prostate cancer cells to TRAIL-mediated apoptosis. Thus, the combination of TRAIL and MSA may be a novel strategy for the development of innovative therapeutic modalities targeting apoptosis-resistant forms of prostate cancer.
Materials and methods

Cell lines and culture conditions
Human prostate cancer cell lines LNCaP and DU-145 were obtained from ATCC (Rockville, MD, USA) and cultured in RPMI 1640 (Bio-Whittaker, Walkersville, MD, USA) supplemented with 10% FCS (Hyclone, Logan, UT, USA), gentamicin (50 mg/l), sodium pyruvate (1 mM) and nonessential amino acids (0.1 mM) under conditions indicated in the figure legends.
Antibodies and reagents
Antibodies to cytochrome c, cFLIP, caspases-3, -8 and -9, BAD (H-5) and PARP were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to Bcl-X L , Bcl-2, c-IAP1, survivin, XIAP, Smac/DIABLO, BAD (#2762), pBAD (Ser112), pBAD (Ser136) were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies to FADD and RIP were purchased from BD Biosciences (San Diego, CA, USA). Antibody to actin, MSA, sodium selenite, seleno-L-methionine and Se-(Methyl)selenocysteine were obtained from Sigma (St Louis, MO, USA). Secondary horseradish peroxidase-conjugated antibodies were purchased from Amersham (Arlington Heights, IL, USA). TRAIL and the pan-caspase inhibitor Z-VAD.fmk were purchased from Biomol (Plymouth Meeting, PA, USA). The APO-BRDU kit was obtained from The Phoenix Flow Systems Inc. (San Diego, CA, USA).
Western blot analysis
Cells were lysed in buffer (50 mM Tris (pH 7.6), 150 mM NaCl, 1% Triton X-100) containing protease inhibitors: aprotinin (5 mg/ml), leupeptin (2 mg/ml) and phenylmethylsulfonyl fluoride (PMSF) (1 mM). Samples were placed on ice for 20 min with occasional vortexing. The cytosolic fraction was prepared using a mitochondrial/cytosol kit according to the protocol provided with the kit (BioVision Inc., Mountain View, CA, USA). Protein concentrations were measured with a commercial kit (Bio-Rad, Richmond, CA, USA). Equivalent amounts of protein (20 mg) were mixed with an equal volume of 2 Â Laemmli sample buffer, boiled, resolved by electrophoresis in sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and transferred to nitrocellulose membrane. Membranes were incubated in blocking solution containing 5% nonfat dry milk overnight to inhibit nonspecific binding. The membranes were then incubated with specific antibody (1-3 mg/ml) for 2 h. After washing in TRIS/0.1% Tween 20 for 30 min, membranes were incubated for another 30 min with horseradish peroxidaseconjugated secondary antibody. The membranes were then washed and developed with enhanced chemiluminescence (ECL Western Blotting Kit, Amersham, Arlington Heights, IL, USA).
Immunocytometry
Surface expression of TRAIL receptor family members was determined by staining cells with FITC-conjugated anti-DR4, -DR5, -DcR1 or -DcR2 antibodies (all from eBioscience, San Diego, CA, USA) for 30 min on ice. Stained cells were washed twice with PBS and analysed by flow cytometry. Analyses were performed on the FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Individual fluorescent populations were determined through the use of acquisition and analysis software (Cell Quest, Becton Dickinson).
Measurement of apoptosis
DNA fragmentation was detected using the APO-BRDU kit (The Phoenix Flow Systems Inc., San Diego, CA, USA) according to the protocol provided with the kit.
Determination of the mitochondrial transmembrane potential
Cells were incubated with 40 nM 3,3 0 -dihexyloxacarbocyanine iodide, DiOC 6 (Molecular Probes Inc., Eugene, OR, USA), in phosphate-buffered saline for 15 min at room temperature. The cells were then washed twice and analysed by flow cytometry.
